Entacapone in Parkinson’s disease

Nuijten, MJ.C., van Iperen, P.O., Palmer, C., ran Hilten, BX, Snyder, E. Cost-effectiveness analysis of entacapone in Parkinson s disease a Markov process analysis. Value Health 4(4), 316-327, 2001. 

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M Celomen Study Group. Efficacy and safety of entacapone in Parkinson s disease patients with suboptimal levodopa response a 6-month randomized placebo-controlled double-bhnd study in Germany and Austria (Celomen study). Acta Neurol Scand 2002 105(4) 245-55. 

---

See also in sourсe #XX -- [ , ]

See also in sourсe #XX -- [ , ]

See also in sourсe #XX -- [ , ]

See also in sourсe #XX -- [ , , ]

---